Clinical trial NCT00793650: Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
Official title: Combination High Dose Melphalan and Autologous PBSC Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Cancer
Multiple Myeloma
Keywords: Cancer
Multiple Myeloma
Peripheral Blood Stem Cell Transplant
Lead sponsor: Emory University
Sponsor class: OTHER
Collaborators: name: Millennium Pharmaceuticals, Inc.
First posted: 2008-11-19
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to evaluate the safety of melphalan and autologous PBSCT (peripheral blood stem cell transplantation - stem cells that come from your own body) in combination with bortezomib, a new FDA approved drug used to treat myeloma.


Eligibility criteria: Inclusion Criteria:

* Patients with multiple myeloma who are eligible for an autologous peripheral blood progenitor transplant
* Male and female subjects between the age of 18 and 70 years.
* Patient has given informed consent prior to any study related procedures with the knowledge that consent can be withdrawn at anytime without prejudice to future medical care
* Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements
* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
* Male subjects agrees to use an acceptable method for contraception for the duration of the study.
* Biopsy proven diagnosis of multiple myeloma from bone marrow aspirate and biopsy prior to study initiation
* Patient has achieved less than 90% disease reduction from previous treatment prior to transplant (as measured by serum or urine protein electrophoresis) and has more than 5% plasma cells in the bone marrow, or patient has progressed and has more than 5% plasma cells in the bone marrow.
* Karnofsky Performance Status score of ≥ 60%
* Patient has met the following laboratory requirements prior to Day -4
* Platelet count ≥ 50, 000/mm3
* Absolute Neutrophil Count ≥ 500/mm3
* Hemoglobin ≥ 10 g/dL (transfusion allowed to meet this criterion)
* Calculated creatinine clearance ≥ 30mL/min
* Toxic effects of previous therapy or surgery resolved to Grade 2 or better

Exclusion Criteria:

* Unsupportable anemia with \< 10b/dL
* Patient has a calculated or measured creatinine clearance of \< 30mL/min within 14 days before enrollment
* Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrollment
* Patient has hypersensitivity to bortezomib, boron or mannitol
* Patient has had an allergic reaction to melphalan or chlorambucil
* Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
* Patient has received other investigational drugs with 14 days before enrollment
* Serious medical or psychiatric illness likely to interfere with participation in this clinical study
* Cardiac or pulmonary dysfunction such that patients do not meet institutional pre-transplant evaluation criteria
* Known central nervous system involvement or suspicion of involvement with Myeloma
* Other active malignancies (with the exception of basal and squamous cell skin cancer) within 5 years of study entry. Patients with treated prostate or cervical cancer in situ who are 2 or more years from therapy and remain free of disease may be entered into the study at the investigator's discretion.
* Known to be HIV positive, HIV-1 positive

Primary outcomes:
measure: Safety and Engraftment
timeFrame: Day 30 after transplant
Secondary outcomes:
measure: Response Rate Using EBMT(European Group for Blood and Bone Marrow Transplan) Criteria at Day +100 After Transplant.
timeFrame: 100 days after transplant
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory University Winship Cancer Institute
state: Georgia
Study officials:
affiliation: Emory University Winship Cancer Institute
name: Sagar Lonial, MD
role: PRINCIPAL_INVESTIGATOR
References: